Ultralife Co. (NASDAQ:ULBI) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in Ultralife Co. (NASDAQ:ULBI) by 13.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,233 shares of the technology company’s stock after acquiring an additional 1,838 shares during the period. Barclays PLC owned approximately 0.09% of Ultralife worth $113,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc purchased a new stake in Ultralife in the 4th quarter worth about $85,000. LSV Asset Management acquired a new stake in Ultralife in the 4th quarter worth approximately $145,000. Perritt Capital Management Inc lifted its position in Ultralife by 100.0% during the 4th quarter. Perritt Capital Management Inc now owns 30,000 shares of the technology company’s stock worth $224,000 after acquiring an additional 15,000 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Ultralife by 35.7% during the 4th quarter. Bank of New York Mellon Corp now owns 43,541 shares of the technology company’s stock valued at $324,000 after purchasing an additional 11,448 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Ultralife by 250.8% in the third quarter. JPMorgan Chase & Co. now owns 47,458 shares of the technology company’s stock valued at $429,000 after acquiring an additional 33,929 shares during the period. 30.68% of the stock is owned by institutional investors.

Ultralife Stock Performance

Shares of NASDAQ ULBI opened at $5.52 on Thursday. The company’s 50 day simple moving average is $4.92 and its 200 day simple moving average is $6.64. The firm has a market capitalization of $91.81 million, a P/E ratio of 10.04 and a beta of 0.77. Ultralife Co. has a fifty-two week low of $4.07 and a fifty-two week high of $12.40. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.30 and a quick ratio of 1.62.

Ultralife (NASDAQ:ULBI) last posted its earnings results on Friday, May 9th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.02). The business had revenue of $50.75 million during the quarter, compared to analyst estimates of $54.50 million. Ultralife had a net margin of 5.44% and a return on equity of 7.92%. During the same period in the previous year, the firm posted $0.21 earnings per share.

Insider Buying and Selling

In other Ultralife news, Director Thomas Louis Saeli purchased 5,000 shares of the business’s stock in a transaction on Wednesday, May 14th. The stock was acquired at an average price of $5.44 per share, with a total value of $27,200.00. Following the acquisition, the director now directly owns 85,000 shares of the company’s stock, valued at $462,400. This trade represents a 6.25% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 39.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Ultralife from a “hold” rating to a “buy” rating in a research report on Monday.

Ultralife Profile

Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.